Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Forsyth

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
Neuro-Oncology|January 29, 2022
Surgical and anatomic factors predict development of leptomeningeal disease in patients with melanoma brain metastasesStephen R Lowe, Christopher P Wang, Amanda Brisco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2025
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain MetastasesSarah A Weiss, Dijana Djureinovic, Wei Wei, et al.
Journal of Neurosurgery|January 22, 2023
Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy aloneAmmoren E Dohm, Joseph D Tang, Matthew N Mills, et al.
Pigment Cell & Melanoma Research|January 10, 2020
Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directionsIsabella C Glitza, Keiran S M Smalley, Priscilla K Brastianos, et al.
Journal of Neuro-Oncology|December 23, 2003
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendrogliomaLauren E Abrey, Barrett H Childs, Nina Paleologos, et al.
Neuro-Oncology|March 10, 2006
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-upLauren E Abrey, Barrett H Childs, Nina Paleologos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2025
Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204Raymond Y Huang, Gilbert Youssef, Thomas Nelson, et al.
Cancer Cell|September 23, 2022
Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responsesJessica K Mandula, Shiun Chang, Eslam Mohamed, et al.
Leukemia|September 19, 2024
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacyAndrew J Innes, Chloe Hayden, Victoria Orovboni, et al.
Neuro-Oncology|May 5, 2017
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendrogliomaAlissa A Thomas, Lauren E Abrey, Robert Terziev, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Neuro-Oncology|January 29, 2022
Surgical and anatomic factors predict development of leptomeningeal disease in patients with melanoma brain metastasesStephen R Lowe, Christopher P Wang, Amanda Brisco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2025
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain MetastasesSarah A Weiss, Dijana Djureinovic, Wei Wei, et al.
Journal of Neurosurgery|January 22, 2023
Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy aloneAmmoren E Dohm, Joseph D Tang, Matthew N Mills, et al.
Pigment Cell & Melanoma Research|January 10, 2020
Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directionsIsabella C Glitza, Keiran S M Smalley, Priscilla K Brastianos, et al.
Journal of Neuro-Oncology|December 23, 2003
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendrogliomaLauren E Abrey, Barrett H Childs, Nina Paleologos, et al.
Neuro-Oncology|March 10, 2006
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-upLauren E Abrey, Barrett H Childs, Nina Paleologos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2025
Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204Raymond Y Huang, Gilbert Youssef, Thomas Nelson, et al.
Cancer Cell|September 23, 2022
Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responsesJessica K Mandula, Shiun Chang, Eslam Mohamed, et al.
Leukemia|September 19, 2024
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacyAndrew J Innes, Chloe Hayden, Victoria Orovboni, et al.
Neuro-Oncology|May 5, 2017
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendrogliomaAlissa A Thomas, Lauren E Abrey, Robert Terziev, et al.
Pageof 8